

On page 9, line 24, before "microcrystalline",  
insert a --,--.

R E M A R K S

The specification was amended in order to correct minor clerical errors. No new matter has been introduced.

With further regard to Example 2 in the above-identified application (see pages 12 to 13), further testing has revealed the results of the activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against the human immunodeficiency virus HIV (HTLV-III LAV) and the ED<sub>50</sub> is  $8.8 \times 10^{-3} \mu\text{M}$  (ED<sub>50</sub> is defined on page 14 of the application). In the patent application, the three levels of compound tested were 1, 10 and 100  $\mu\text{M}$ . This was extended to lower concentrations as follows:

<u>Concentration (uM)</u>	<u>Percent Inhibition</u>
0.001	11
0.01	64
0.1	81
1.0	99
10.0	100

Respectfully submitted,  
SPRUNG HORN KRAMER & WOODS

By Richard S. Barth  
Richard S. Barth  
Reg. No. 28,180

600 Third Avenue  
New York, NY 10016  
(212) 661-0520